

Figure S1. Validation of plasma exosomes of patients with pre- and post-radiotherapy. (A and B) Size validation of plasma exosomes. (C and D) Sample concentration of plasma exosomes.








Figure S2. Histone gram of GO analysis in the down- and upregulated targets. (A) GO analysis of upregulated targets. (B) GO analysis of downregulated targets. GO, Gene Ontology.





Figure S3. Top 20 biological processes of GO analysis in the down- and upregulated targets. (A) Top 20 BPs in upregulated targets. (B) Top 20 BPs in downregulated targets. GO, Gene Ontology; BP, Biological Process.




Figure S4. Circles graph of KEGG analysis in the down- and upregulated targets. (A) KEGG analysis of upregulated targets. (B) KEGG analysis of downregulated targets. KEGG, Kyoto Encyclopedia of Genes and Genomes.




Figure S5. Bubble chart of DO analysis of the down- and upregulated targets. (A) DO analysis of upregulated targets. (B) DO analysis of downregulated targets. DO, Disease Ontology.





Figure S6. Cell proliferation after overexpression and inhibition of miR-652 and miR-30a. (A and B) CCK-8 assay of overexpression and inhibition of miR-652. (C and D) CCK-8 assay of overexpression and inhibition of miR-30a. miR, microRNA; CCK-8, Cell Counting Kit-8; NC, negative control.

